Stapled peptides modulated amyloid-beta aggregation and disrupted preformed fibrils while showing improved proteolytic stability — a dual-action approach to Alzheimer's disease.
Dual actionprevents new amyloid-beta aggregation AND disrupts preformed fibrils — addressing both disease prevention and existing pathology
What the researchers found
The team used a "tail-to-side chain" stapling method to create a library of modified peptides. These stapled peptides modulated the self-association and fibril formation of amyloid-beta 1-40, the protein fragment central to Alzheimer's pathology.
The stapled peptides also disrupted preformed fibrillar aggregates, converting them into non-toxic species. This dual action, preventing new aggregation and breaking up existing fibrils, is particularly valuable.
The ring shape made the peptides significantly more resistant to proteolytic enzymes, which would normally break down linear peptides quickly. This improved stability is essential for any potential therapeutic use.
Why it matters
Alzheimer's disease has no effective treatment targeting amyloid aggregation. Finding peptides that can both prevent new clumps and break up existing ones addresses two aspects of the disease at once.
The improved enzyme resistance from stapling solves a major problem with peptide drugs, which usually get broken down too quickly to be useful.
The numbers in context
Library of stapled peptides; modulated Aβ1-40 aggregation; disrupted preformed fibrils; increased proteolytic stability
How the study worked
This was a laboratory study. Researchers synthesized stapled peptides through lactamization (forming a ring via a chemical bond). They tested the peptides against amyloid-beta 1-40 aggregation using standard fibrillogenesis assays and evaluated proteolytic stability in the presence of enzymes.
Who was studied
Amyloid-beta 1-40 protein (lab study)
What this study cannot tell us
This was entirely a lab study with no cell viability, animal, or human testing. Whether these peptides can cross the blood-brain barrier and work in a living brain is unknown.
The non-toxic nature of the disrupted aggregates was stated but the extent of toxicity testing was limited.
How to read the evidence
Preliminary evidence from in vitro studies. No cell viability, blood-brain barrier penetration, or animal data.
When this study was published
Published in 2020. The Alzheimer's treatment landscape has evolved with approval of anti-amyloid antibodies since this study.
The bigger picture
Alzheimer's disease has no effective amyloid-targeting treatment despite decades of effort. Peptides that can both prevent new aggregation and dissolve existing deposits address the disease at two stages, potentially offering more benefit than agents targeting only one.
Questions still open
- Can these stapled peptides cross the blood-brain barrier?
- How do they compare to anti-amyloid antibodies like lecanemab?
- Would they be effective at the stage of disease where amyloid is already widespread?
Common questions
What is amyloid-beta and why target it in Alzheimer's?
How are stapled peptides different from anti-amyloid antibodies?
Read the original research
Peptidomimetics prepared by tail-to-side chain one component peptide stapling inhibit Alzheimer's amyloid-β fibrillogenesis.
Chemical science, 11(16), 4171-4179
Citation
Kalita, Sujan; Kalita, Sourav; Paul, Ashim; Sarkar, Amar; Mandal, Bhubaneswar. (2020). Peptidomimetics prepared by tail-to-side chain one component peptide stapling inhibit Alzheimer's amyloid-β fibrillogenesis.. Chemical science, 11(16), 4171-4179. https://doi.org/10.1039/c9sc06076f